medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 2

<< Back Next >>

Ann Hepatol 2012; 11 (2)

Liver transplantation for autoimmune hepatitis in Peru: outcomes and recurrence

Padilla M, Mayorga R, Carrasco F, Bedregal T, Bobadilla F, Rondón C, Chaman J

Language: English
References: 30
Page: 222-227
PDF size: 85.47 Kb.


ABSTRACT

Background. Liver transplantation is the only therapy for end-stage liver disease. Cirrhosis secondary to autoimmune hepatitis (AIH) is an indication in 4-6% of adult transplants. Aims. To describe the outcomes and recurrence of AIH in liver transplant patients. Material and methods. Twenty patients were retrospectively studied. Results. The female/male ratio was 3:1, the median age was 36.7 years (range, 16 to 39 years), and the median MELD score was 18.5. According to serological analysis, 19 patients were AIH type 1 and one patient was AIH type 2. AIH was associated with human leukocyte antigen (HLA) DR13+ and DR4+. The overall 5-year patient and graft survival rates were 94 and 85%, respectively. Three (15.7%) cases of recurrent AIH were diagnosed based on histological evidence. Clinical and histological features of acute and chronic rejection were present in four (20%) and three (16.6%) patients, respectively. Conclusion. AIH frequently affected young women, was the most frequent indication for liver transplantation. Rejection and recurrence were commonly associated with AIH, but did not affect patient survival. No significant relationship between HLA-DR type and recurrence was found. Rapid progression to cirrhosis should be considered in severe recurrences.


REFERENCES

  1. Czaja A, Manns M. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.

  2. Verslype C, George C, Buchel E, Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21: 695-9.

  3. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: Indications, results and management of recurrent disease. Semin Liver Dis 2009; 29: 286-96.

  4. Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, Hoover TC. Incidence and recurrence of autoimmune/ alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002; 8: 519-26.

  5. Duclos-Vallee J, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis and autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15: S25-S34.

  6. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.

  7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.

  8. Decock S, McGee P, Hirschfield GM. Autoimmune liver disease for the non-specialist. BMJ 2009; 339: b3305.

  9. Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 6: 2193-2213.

  10. Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, Al-Sofayan M, et al. Liver transplantation for autoimmune hepatitis: a single center experience. Transplant Proc 2007; 39: 1166–1170.

  11. Antonini T, Samuel D. Indications et résultats de la greffe hépatique (hors carcinome hépatocellulaire et hépatite fulminante). Gastroenterol Clin Biol 2009; 33: 44-50.

  12. Popescu I, Lonescu M, Brasoveanu V, Hrehoret D, Matei E, Dorobantu, Zamfir R et al. Liver transplantation indications, surgical technique, results: the analysis of a clinical series of 200 cases. Chirurgia 2010 Mar-Apr; 105: 177-86.

  13. Sociedad Española de Trasplante Hepático. Consensus document of the Spanish Society of Liver Transplantation. Access to liver transplant, indications, controversies, prioritization of waiting lists and quality indicators. Cir Esp 2008; 83: 290-300.

  14. Reich D, Fiel I, Guarrera J, Emre S, Guy S, Schwartz M, Miller CM, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32(4):693-700..

  15. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.

  16. Czaja A. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant disease and non-white patients. Semin Liver Dis 2009; 29: 315-30.

  17. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leucocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-706.

  18. Narumi K, Hakamada M, Sasaki CE, Freise PG, Stock JP, Roberts NL, Ascher NL. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 1999; 31: 1955-6.

  19. Longi S, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010; 34: 7-14.

  20. Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302-308.

  21. Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badia I, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41: 146-50 [Abstract].

  22. Gotz G, Neuhaus R, Bechstein W, Lobeck H, Berg T, Hopf U, Neuhaus P. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999; 31: 430-1.

  23. Duclos-Valle J, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, Karam V, et al. A ten year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003; 52: 893-897.

  24. Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, Farahmand H, et al. Long term follow up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30:131-141.

  25. Prados E, Cuervas-Mons V, de la Mata M, Fraga E, Rimola A, Prieto M, Clemente G, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998; 66: 1645-1650.

  26. Milkiewics P, Hubscher S, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68: 253-6.

  27. González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 302-310.

  28. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J et al. Long term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62-69.

  29. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12: 1813-24.

  30. Montano-Loza A, Mason A, Ma M, Bastiampillai R, Bain V, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15: 1254-61.




2020     |     www.medigraphic.com